Bivalirudin
Also known as: Angiomax, Angiox
Key Facts: Bivalirudin
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - PCI anticoagulation
- Administration
- IV bolus and infusion
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- Duration of procedure
Mechanism of Action
Bivalirudin is a direct thrombin inhibitor, meaning it blocks thrombin itself rather than working through antithrombin the way heparin does. It is bivalent: one end binds thrombin's active catalytic site and the other binds exosite 1, the spot thrombin uses to grab fibrinogen, so it clamps the enzyme from two angles at once. A key advantage over heparin is that it inhibits clot-bound thrombin, not just free-floating thrombin, which heparin largely misses. The binding is reversible and short-lived, and thrombin slowly cleaves the molecule, so anticoagulation wears off relatively predictably after the infusion stops.
Research Summary
Bivalirudin has been tested head to head against heparin in multiple large randomized PCI and acute coronary syndrome trials, so the human evidence base is substantial. The consistent finding across these trials is comparable protection against ischemic events with meaningfully less bleeding, which matters because bleeding complications drive a lot of harm after stenting. Some analyses reported lower net adverse clinical events with bivalirudin versus heparin combined with a glycoprotein IIb/IIIa inhibitor. Research has also shown it behaves as a dual inhibitor, blunting both thrombin activity and collagen-dependent platelet activation in patients undergoing PCI. The literature is not unanimous, and newer trials and meta-analyses have refined exactly which patients benefit most, including discussion of stent thrombosis risk in the hours after the procedure. Bottom line: this is a well-studied approved anticoagulant, and the debate is about optimal use, not whether it works.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Procedural use
Doses from Studies
0.75 mg/kg IV bolus
1.75 mg/kg/h infusion during procedure
Duration
Duration of procedure
Administration
IV bolus and infusion
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Bleeding (28%)
- ●Headache
- ●Thrombocytopenia
- ●Hypotension
- ●Acute stent thrombosis (higher than heparin)
- ●Allergic reactions
- ●FDA approved (Angiomax)
References
- https://www.ncbi.nlm.nih.gov/books/NBK557823/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1994003/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3086141/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5059288/
Research This Peptide Further
Frequently Asked Questions
What does Bivalirudin do?
Bivalirudin is an FDA-approved anticoagulant (brand name Angiomax) and a synthetic 20 amino acid peptide based on hirudin, the natural anticlotting molecule from medicinal leeches. It is given intravenously during PCI and in some acute coronary syndrome and heparin-induced-thrombocytopenia situations to prevent clots while keeping bleeding lower than older drugs. This is a hospital-grade prescription anticoagulant with a long clinical track record, approved by the FDA in 2000.
How does Bivalirudin work?
Bivalirudin is a direct thrombin inhibitor, meaning it blocks thrombin itself rather than working through antithrombin the way heparin does. It is bivalent: one end binds thrombin's active catalytic site and the other binds exosite 1, the spot thrombin uses to grab fibrinogen, so it clamps the enzyme from two angles at once. A key advantage over heparin is that it inhibits clot-bound thrombin, not just free-floating thrombin, which heparin largely misses. The binding is reversible and short-lived, and thrombin slowly cleaves the molecule, so anticoagulation wears off relatively predictably after the infusion stops.
Is Bivalirudin FDA approved?
Yes, Bivalirudin is FDA approved. FDA Approved - PCI anticoagulation
What are the side effects of Bivalirudin?
Reported side effects include: Bleeding (28%), Headache, Thrombocytopenia, Hypotension, Acute stent thrombosis (higher than heparin). Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Bivalirudin?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: IV bolus and infusion. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Bivalirudin or used in similar applications.
Oxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalGonadorelin
FDAGonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.
HormonalLeuprolide
FDALeuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.
HormonalDesmopressin
FDADesmopressin (dDAVP) is a synthetic tweak of the natural hormone vasopressin, redesigned to keep the water-retaining effect while dropping most of the blood-pressure effect. It is a long-established FDA-approved drug used for central diabetes insipidus, bedwetting and nocturia, and certain bleeding disorders like von Willebrand disease and mild hemophilia A. This is settled medicine, not an experimental peptide, and its main real-world danger is straightforward: it can drop your blood sodium dangerously low if you drink too much fluid on it.
HormonalOctreotide
FDAOctreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).
HormonalLanreotide
FDALanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.
HormonalWant updates on Bivalirudin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.